Highlights Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
4.87 ^USD	+16.23%		+22.98%	-13.81%

Jun. 27	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160	CI
Jun. 14	Monte Rosa Therapeutics, Inc. Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160	Jun. 27	CI
Monte Rosa Therapeutics, Inc. Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	Jun. 14	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	May. 16	MT
Monte Rosa Therapeutics Prices $100 Million Public Offering	May. 16	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	Mar. 14	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	Mar. 11	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Monte Rosa Therapeutics Partners With Roche in Targeting Cancer, Neurological Diseases; Shares Surge Pre-Bell	23-10-17	MT
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors	23-10-17	CI
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases	23-10-17	CI
Monte Rosa Says on Track to File Application for Autoimmune Diseases Treatment, Provide Initial Data on Solid Tumors Therapy	23-08-10	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Monte Rosa Therapeutics Advances Second Development Candidate	23-05-23	MT
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases	23-05-23	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Monte Rosa Therapeutics, Inc. Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023	23-04-17	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Highlights

Filters